Correction of the zygomatic region is a key moment in facial rejuvenation. When the volume of the cheekbones is restored, the lower third of the face is automatically lifted, the nasolabial folds are reduced, and the oval of the face becomes more apparent. This case presents a method for injecting dermal fillers to restore the volume of the cheekbones.
The patient came to the clinic with the problem of insufficient cheekbones volume and the initial manifestations of the deformative type of aging which is characteristic for the inhabitants of our region. The deformation type of aging is characterized by a predominance of facial tissues swelling and drooping, pronounced laxity, especially in the middle and lower third of the face. Along with this, wrinkles and pigmentation disorders are not typical, the skin is dense enough, shiny, sometimes porous, as in this case. Since the patient was not ready for lipofilling or surgical implantation, we have decided to correct the cheekbones with fillers. The choice of a cheekbone volumetric preparation is very important.
This is due to the fact that the tissues in this area are quite heavy. The product of choice was Genefill DX from the Genefill dermal fillers line, a new generation of bi-phaseic HA fillers. The safety of their use is confirmed by the international quality certificate CE (Conformité Européenne). Genefill contains crosslinked HA particles integrated into uncrosslinked HA carriers.
The basis of the entire Genefill line is the Advanced Thixotropic Technology solution, patented by BioScience (Germany), which determines the
behavior of gel molecules during and after injection. It is aimed at optimizing the injection procedure as much as possible and providing the most
desirable properties of hyaluronic dermatological fillers: smooth injection, high degree of stability and predictability of the result.
Through a special manufacturing process, the thixotropic molecules in Genefill have the ability to become less viscous under piston pressure upon injection. Therefore, Genefill products are easier to implant with smaller needles, while minimizing pain levels and maximizing patient comfort during the procedure.
Hyaluronic acid molecules in conventional gels tend to degrade under the influence of injection pressure, which negatively affects the duration of fillers’ duration in the injection area and, consequently, reduces the effectiveness of their use in dermatology. The thixotropic molecules in Genefill (unlike other gels) return to their original viscosity after injection, thus providing a long lasting and stable effect.
Additionally, 1 ml of Genefill DX alone contains 50 mg of dextranomer microparticles, which stimulates endogenous growth of collagen fibers and has pronounced anti-in-flammatory properties. Due to this, a decrease in edema at the injection area is achieved and the duration of the drug’s stay in tissues is increased.